Liquid biopsies for diagnosing and monitoring primary tumors of the central nervous system

Le Rhun, Emilie; Seoane, Joan; Salzet, Michel; Soffietti, Riccardo; Weller, Michael

Document type :

Article dans une revue scientifique: Article original

DOI :

10.1016/j.canlet.2020.03.021

PMID :

32229189

Permalink :

http://hdl.handle.net/20.500.12210/75155

Title :

Liquid biopsies for diagnosing and monitoring primary tumors of the central nervous system

Author(s) :

Le Rhun, Emilie [Auteur]

Protéomique, Réponse Inflammatoire, Spectrométrie de Masse (PRISM) - U1192
University hospital of Zurich [Zurich]
Universität Zürich [Zürich] = University of Zurich [UZH]
Seoane, Joan [Auteur]
Salzet, Michel [Auteur]

Protéomique, Réponse Inflammatoire, Spectrométrie de Masse (PRISM) - U1192
Soffietti, Riccardo [Auteur]
Weller, Michael [Auteur]

Journal title :

Cancer Letters

Abbreviated title :

Cancer Lett.

Volume number :

480

Pages :

24-28

Publisher :

Elsevier

Publication date :

2020-03-27

ISSN :

0304-3835

English keyword(s) :

Biopsy
Brain
CSF
Glioma
Liquid
Plasma
Tumor

HAL domain(s) :

Sciences du Vivant [q-bio]

English abstract : [en]

Obtaining diagnostic specimens, notably to monitor disease course in cancer patients undergoing therapy, is an emerging area of research, however, with few clinical implications so far in the field of Neuro-oncology. ...
Show more >Obtaining diagnostic specimens, notably to monitor disease course in cancer patients undergoing therapy, is an emerging area of research, however, with few clinical implications so far in the field of Neuro-oncology. Specifically for patients with primary brain tumors where repeat biosampling from the tumor and clinical decision making based on neuroimaging alone remain challenging, this area may assume a central role. In principle, sampling could focus on blood, cerebrospinal fluid or urine with differential sensitivities and specificities of findings that differ between specific parameters and target molecules. These include protein, mRNA, miRNA, cell-free DNA, either freely circulating or as cargo of extracellular vesicles, as well circulating tumor cells. The most solid biomarkers are those directly reflecting neoplastic disease, e.g., in the case of primary brain tumors isocitrate dehydrogenase mutation or epidermal growth factor receptor variant III. Importantly, the main goals of liquid biopsy marker development are to better understand response to therapy, natural evolution and emergence of resistant clones, rather than obviating the need for surgical interventions which remain to be a mainstay of therapy for the vast majority of primary brain tumors.Show less >

Language :

Anglais

Peer reviewed article :

Oui

Audience :

Internationale

Popular science :

Non

Administrative institution(s) :

INSERM
Université de Lille

Collections :

Protéomique, Réponse Inflammatoire, Spectrométrie de Masse (PRISM) - U1192

Submission date :

2022-06-15T13:59:28Z
2023-03-07T10:43:14Z

Files

2020-03-27-Le_Rhun_Sammelmappe1.pdf
Version éditeur
Open access
Access the document

Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivs 3.0 United States

Version	Link	Modification date
2	20.500.12210/75155*	2023-03-07T10:35:33Z
1	20.500.12210/75155.1	2022-06-15T13:59:28Z

Liquid biopsies for diagnosing and monitoring ...

BibTeX

CSV

Excel

RIS

Files

Version history

Liquid biopsies for diagnosing and monitoring ... BibTeX CSV Excel RIS

Files

Version history

Liquid biopsies for diagnosing and monitoring ...

BibTeX

CSV

Excel

RIS